Eloxx Pharmaceuticals (ELOX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ELOX vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Eloxx Pharmaceuticals vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Eloxx Pharmaceuticals (NASDAQ:ELOX) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Is ELOX or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Eloxx PharmaceuticalsN/A N/A N/A 180 Life Sciences N/A N/A N/A Which has stronger valuation & earnings, ELOX or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEloxx PharmaceuticalsN/AN/A-$36.06MN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the media favor ELOX or ATNFW? In the previous week, 180 Life Sciences had 4 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 5 mentions for 180 Life Sciences and 1 mentions for Eloxx Pharmaceuticals. 180 Life Sciences' average media sentiment score of 1.01 beat Eloxx Pharmaceuticals' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 180 Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ELOX or ATNFW? 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryEloxx Pharmaceuticals and 180 Life Sciences tied by winning 2 of the 4 factors compared between the two stocks. Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELOX vs. The Competition Export to ExcelMetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$282.60M$5.67B$9.82BDividend YieldN/AN/A3.79%4.07%P/E RatioN/AN/A30.8025.13Price / SalesN/A571.06466.77115.19Price / CashN/A22.4437.4059.05Price / BookN/A9.819.096.18Net Income-$36.06M-$115.81M$3.26B$265.11M Eloxx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0030News CoverageATNFW180 Life SciencesN/A$0.11+834.2%N/A+4,157.4%$0.00N/A0.007News CoverageGap UpHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-87.3%$0.00N/A0.002AIMDWAinosN/A$0.43-4.0%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.40+5.3%N/A-66.2%$0.00$585.60M0.004Positive NewsGap UpHigh Trading VolumeARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.04-30.8%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.14flatN/A+118.7%$0.00$38.00M0.0070Positive NewsBTMDWbioteN/A$0.01-9.9%N/AN/A$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.03-5.1%N/A-87.6%$0.00N/A0.008Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors ARAVIVE Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELOX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredJPMorgan: Gold to $4,250—Here’s the Real PlayGold Surges And Some Investors Are Getting Paid, But Most Are Not. Which One Do You Want to Be? Gold prices ar...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access